Citation Total Citations
Citations per Year 1 Abrams, P., Schulman, C. C., Vaage, S., Abel, P., Baxby, K., Boeminghaus, F., . . .
Ypma, A. (1995). TAMSULOSIN, A SELECTIVE ALPHA(1C)-ADRENOCEPTOR ANTAGONIST - A RANDOMIZED, CONTROLLED TRIAL IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION (SYMPTOMATIC BPH). British Journal of Urology, 76(3), 325-336. doi:10.1111/j.1464-410X.1995.tb07709.x
184 8.00
2 Al-Ansari, A., Younes, N., Sampige, V. P., Al-Rumaihi, K., Ghafouri, A., Gul, T., & Shokeir, A. A. (2010). Green Light HPS 120-W Laser Vaporization Versus
Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia: A Randomized Clinical Trial with Midterm Follow-up. European Urology, 58(3), 349-355. doi:10.1016/j.eururo.2010.05.026
154 19.25
3 Barrow, J. C., Nantermet, P. G., Selnick, H. G., Glass, K. L., Rittle, K. E., Gilbert, K. F., . . . Forray, C. (2000). In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. Journal of Medicinal Chemistry, 43(14), 2703-2718. doi:10.1021/jm990612y
185 10.28
4 Barry, M. J. (1990). EPIDEMIOLOGY AND NATURAL-HISTORY OF BENIGN PROSTATIC HYPERPLASIA. Urologic Clinics of North America, 17(3), 495-507.
173 6.18
5 Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., & Mebust, W. K. (1995). MEASURING DISEASE-SPECIFIC HEALTH-STATUS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. Medical Care, 33(4), AS145-AS155.
143 6.22
6 Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., . . . Wein, A. J. (1992). THE
AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 148(5), 1549-1557. doi:10.1016/s0022-5347(17)36966-5
2042 78.54
7 Bartsch, G., Muller, H. R., Oberholzer, M., & Rohr, H. P. (1979). LIGHT
MICROSCOPIC STEREOLOGICAL ANALYSIS OF THE NORMAL HUMAN-PROSTATE AND OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 122(4), 487-491. doi:10.1016/s0022-5347(17)56476-9
229 5.87
8 Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., & Avins, A. L. (2006). Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 354(6), 557-566. doi:10.1056/NEJMoa053085
205 17.08
9 Berges, R. R., Windeler, J., Trampisch, H. J., Senge, T., Aeikens, B., Albrecht, J., . . . Schumacher, C. (1995). RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL-TRIAL OF BETA-SITOSTEROL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Lancet, 345(8964), 1529-1532. doi:10.1016/s0140-6736(95)91085-9
155 6.74
10 Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984). THE
DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE. Journal of Urology, 132(3), 474-479. doi:10.1016/s0022-5347(17)49698-4
1366 40.18
11 Boyle, P., Gould, A. L., & Roehrborn, C. G. (1996). Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis
of randomized clinical trials. Urology, 48(3), 398-405. doi:10.1016/s0090-4295(96)00353-6
12 Carson, C., & Rittmaster, R. (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(4), 2-7. doi:10.1016/s0090-4295(03)00045-1
165 11.00
13 Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A., & Abrams, P. (1996). Tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist - A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Urology, 29(2), 155-167
207 9.41
14 Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. Journal of Clinical Endocrinology & Metabolism, 89(5), 2179-2184. doi:10.1210/jc.2003-030330
232 16.57
15 Coffey, D. S., & Walsh, P. C. (1990). CLINICAL AND EXPERIMENTAL
STUDIES OF BENIGN PROSTATIC HYPERPLASIA. Urologic Clinics of North America, 17(3), 461-475.
157 5.61
16 Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., . . . Scher, H. I. (1998). Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma. Journal of the National Cancer
Institute, 90(17), 1284-1291. doi:10.1093/jnci/90.17.1284
222 11.10
17 Dahle, S. E., Chokkalingam, A. P., Gao, Y. T., Deng, J., Stanczyk, F. Z., & Hsing, A. W. (2002). Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. Journal of Urology, 168(2), 599-604.
doi:10.1016/s0022-5347(05)64687-3
146 9.13
18 De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schroder, F., . . . Tubaro, A. (2011). The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology, 60(1), 106-117. doi:10.1016/j.eururo.2011.03.055
159 22.71
19 Debruyne, F., Barkin, J., van Erps, P., Reis, M., Tammela, T. L. J., Roehrborn, C., . . . Investigators, A. S. (2004). Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. European Urology, 46(4), 488-495. doi:10.1016/j.eururo.2004.05.008
149 10.64
20 Debruyne, F. M. J., Jardin, A., Colloi, D., Resel, L., Witjes, W. P. J., Delauche-Cavallier, M. C., . . . European, A. S. G. (1998). Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European Urology, 34(3), 169-175. doi:10.1159/000019706
163 8.15
21 Di Silverio, F., Gentile, V., De Matteis, A., Mariotti, G., Giuseppe, V., Luigi, P. A., & Sciarra, A. (2003). Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. European Urology, 43(2), 164-175. doi:10.1016/s0302-2838(02)00548-1
140 9.33
22 Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K., & Dias, N. (1995).
DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN NORMOTENSIVE PATIENTS - A MULTICENTER STUDY. Journal of Urology, 154(1), 105-109. doi:10.1016/s0022-5347(01)67240-9
B., . . . Matusik, R. J. (1986). EXPRESSION OF THE CIS-MYC
PROTOONCOGENE IN HUMAN PROSTATIC-CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA. Cancer Research, 46(3), 1535-1538
24 Fulton, B., Wagstaff, A. J., & Sorkin, E. M. (1995). DOXAZOSIN - AN UPDATE OF ITS CLINICAL-PHARMACOLOGY AND THERAPEUTIC APPLICATIONS IN HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA. Drugs, 49(2), 295-320. doi:10.2165/00003495-199549020-00011
144 6.26
25 Gacci, M., Corona, G., Salvi, M., Vignozzi, L., McVary, K. T., Kaplan, S. A., . . . Maggi, M. (2012). A Systematic Review and Meta-analysis on the Use of
Phosphodiesterase 5 Inhibitors Alone or in Combination with alpha-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. European Urology, 61(5), 994-1003. doi:10.1016/j.eururo.2012.02.033
145 24.17
26 Garraway, W. M., Russell, E., Lee, R. J., Collins, G. N., McKelvie, G. B., Hehir, M., . . . Simpson, R. J. (1993). IMPACT OF PREVIOUSLY UNRECOGNIZED
BENIGN PROSTATIC HYPERPLASIA ON THE DAILY ACTIVITIES OF MIDDLE-AGED AND ELDERLY MEN. British Journal of General Practice, 43(373), 318-321.
141 5.64
27 Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K., & Dias, N. (1995). DOXAZOSIN FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION - A DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RESPONSE MULTICENTER STUDY. Journal of Urology, 154(1), 110-115. doi:10.1016/s0022-5347(01)67243-4
153 6.65
28 Giovannucci, E., Rimm, E. B., Chute, C. G., Kawachi, I., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994). OBESITY AND BENIGN PROSTATIC
HYPERPLASIA. American Journal of Epidemiology, 140(11), 989-1002. doi:10.1093/oxfordjournals.aje.a117206
162 6.75
29 Glynn, R. J., Campion, E. W., Bouchard, G. R., & Silbert, J. E. (1985). THE DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA AMONG VOLUNTEERS IN THE NORMATIVE AGING STUDY. American Journal of Epidemiology, 121(1), 78-90.
272 8.24
30 Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperatomcginley, J., Walsh, P. C., McConnell, J. D., . . . Ng, J. (1992). THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. New England Journal of Medicine, 327(17), 1185-1191. doi:10.1056/nejm199210223271701
836 32.15
31 Griffiths, D., Vanmastrigt, R., & Bosch, R. (1989). QUANTITIFICATION OF URETHRAL RESISTANCE AND BLADDER FUNCTION DURING VOIDING, WITH SPECIAL REFERENCE TO THE EFFECTS OF PROSTATE
SIZE-REDUCTION ON URETHRAL OBSTRUCTION DUE TO BENIGN PROSTATIC HYPERPLASIA. Neurourology and Urodynamics, 8(1), 17-27.
doi:10.1002/nau.1930080104
148 5.10
32 Hammarsten, J., & Hogstedt, B. (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European Urology, 39(2), 151-158. doi:10.1159/000052430
33 Hammarsten, J., Hogstedt, B., Holthuis, N., & Mellstrom, D. (1998). Components of the metabolic syndrome - risk factors for the development of benign prostatic
hyperplasia. Prostate Cancer and Prostatic Diseases, 1(3), 157-162. doi:10.1038/sj.pcan.4500221
178 8.90
34 Kawabe, K., Yoshida, M., Homma, Y., & Silodosin Clin Study, G. (2006). Silodosin, a new alpha(1A)-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Bju International, 98(5), 1019-1024.
doi:10.1111/j.1464-410X.2006.06448.x
165 13.75
35 Kenny, B., Ballard, S., Blagg, J., & Fox, D. (1997). Pharmacological options in the treatment of benign prostatic hyperplasia. Journal of Medicinal Chemistry, 40(9), 1293-1315. doi:10.1021/jm960697s
154 7.33
36 Kirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M., . . . Pedict Study, I. (2003). Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 61(1), 119-126. doi:10.1016/s0090-4295(02)02114-3
221 14.73
37 Kramer, G., Mitteregger, D., & Marberger, M. (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology, 51(5), 1202-1216. doi:10.1016/j.eururo.2006.12.011
236 21.45
38 Krieg, M., Klotzl, G., Kaufmann, J., & Voigt, K. D. (1981). STROMA OF HUMAN BENIGN PROSTATIC HYPERPLASIA - PREFERENTIAL TISSUE FOR
ANDROGEN METABOLISM AND ESTROGEN BINDING. Acta Endocrinologica, 96(3), 422-432.
144 3.89
39 Kurhanewicz, J., Vigneron, D. B., Nelson, S. J., Hricak, H., Macdonald, J. M., Konety, B., & Narayan, P. (1995). CITRATE AS AN IN-VIVO MARKER TO DISCRIMINATE PROSTATE-CANCER FROM BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATE PERIPHERAL ZONE -
DETECTION VIA LOCALIZED PROTON SPECTROSCOPY. Urology, 45(3), 459-466. doi:10.1016/s0090-4295(99)80016-8
147 6.39
40 Lepor, H. (1995). LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Urology, 45(3), 406-413. doi:10.1016/s0090-4295(99)80008-9
271 13.55
41 Lepor, H., & Tamsulosin Investigator, G. (1998). Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of Phase III trial. Urology, 51(6), 901-906. doi:10.1016/s0090-4295(98)00127-7
151 7.55
42 Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., . . . Padley, R. J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New England Journal of Medicine, 335(8), 533-539. doi:10.1056/nejm199608223350801
149 6.48
43 Lepor, H., Auerbach, S., Purasbaez, A., Narayan, P., Soloway, M., Lowe, F., . . . Madsen, P. (1992). A RANDOMIZED, PLACEBO-CONTROLLED
MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 148(5), 1467-1474. doi:10.1016/s0022-5347(17)36941-0
. . . Padley, R. J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New England Journal of Medicine, 335(8), 533-539. doi:10.1056/nejm199608223350801
45 Luo, J., Duggan, D. J., Chen, Y. D., Sauvageot, J., Ewing, C. M., Bittner, M. L., . . . Isaacs, W. B. (2001). Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Research, 61(12), 4683-4688.
374 22.00
46 Madersbacher, S., Alivizatos, G., Nordling, J., Sanz, C. R., Emberton, M., & de la Rosette, J. (2004). EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). European Urology, 46(5), 547-554.
doi:10.1016/j.eururo.2004.07.016
404 28.86
47 Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., & Adaml, H. O. (1997). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76(9), 1115-1118.
doi:10.1038/bjc.1997.520
284 13.52
48 Maria, G., Brisinda, G., Civello, I. M., Bentivoglio, A. R., Sganga, G., & Albanese, A. (2003). Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology, 62(2), 259-264. doi:10.1016/s0090-4295(03)00477-1
167 11.13
49 McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., . . . Finasteride Long-Term Eff Saf Study, G. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New England Journal of Medicine, 338(9), 557-563. doi:10.1056/nejm199802263380901
732 36.60
50 McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., . . . Grp, M. R. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 349(25), 2387-2398. doi:10.1056/NEJMoa030656
1036 69.07
51 McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Pappas, F., & Stoner, E. (1992). FINASTERIDE, AN INHIBITOR OF 5-ALPHA-REDUCTASE,
SUPPRESSES PROSTATIC DIHYDROTESTOSTERONE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Clinical Endocrinology & Metabolism, 74(3), 505-508. doi:10.1210/jc.74.3.505
266 10.23
52 McNeal, J. (1990). PATHOLOGY OF BENIGN PROSTATIC HYPERPLASIA - INSIGHT INTO ETIOLOGY. Urologic Clinics of North America, 17(3), 477-486.
209 7.46
53 McVary, K. T., Monnig, W., Camps, J. L., Young, J. M., Tseng, L. J., & van den Ende, G. (2007). Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. Journal of Urology, 177(3), 1071-1077. doi:10.1016/j.juro.2006.10.055
234 21.27
54 McVary, K. T., Roehrborn, C. G., Avins, A. L., Barry, M. J., Bruskewitz, R. C., Donnell, R. F., . . . Wei, J. T. (2011). Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. Journal of Urology, 185(5), 1793-1803.
doi:10.1016/j.juro.2011.01.074
55 McVary, K. T., Roehrborn, C. G., Kaminetsky, J. C., Auerbach, S. M., Wachs, B., Young, J. M., . . . Denes, B. S. (2007). Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology, 177(4), 1401-1407. doi:10.1016/j.juro.2006.11.037
234 21.27
56 McVary, K. T. (2006). BPH: Epidemiology and comorbidities. American Journal of Managed Care, 12(5), S122-S128.
168 14.00
57 McVary, K. T. (2005). Erectile dysfunction and lower urinary tract symptoms secondary to BPH. European Urology, 47(6), 838-845.
doi:10.1016/j.eururo.2005.02.001
140 10.77
58 McVary, K. T., Rademaker, A., Lloyd, G. L., & Gann, P. (2005). Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Urology, 174(4), 1327-1333.
doi:10.1097/01.ju.0000173072.73702.64
145 11.15
59 Meigs, J. B., Mohr, B., Barry, M. J., Collins, M. M., & McKinlay, J. B. (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. Journal of Clinical Epidemiology, 54(9), 935-944.
doi:10.1016/s0895-4356(01)00351-1
222 13.06
60 Montorsi, F., Naspro, R., Salonia, A., Suardi, N., Briganti, A., Zanoni, M., . . . Rigatti, P. (2004). Holmium laser enucleation versus transurethral resection of the prostate: Results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. Journal of Urology, 172(5), 1926-1929. doi:10.1097/01.ju.0000140501.68841.a1
158 11.29
61 Mori, H., Maki, M., Oishi, K., Jaye, M., Igarashi, K., Yoshida, O., & Hatanaka, M. (1990). INCREASED EXPRESSION OF GENES FOR BASIC FIBROBLAST GROWTH-FACTOR AND TRANSFORMING GROWTH-FACTOR TYPE-BETA-2 IN HUMAN BENIGN PROSTATIC HYPERPLASIA. Prostate, 16(1), 71-80. doi:10.1002/pros.2990160108
169 6.04
62 Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J., & Ratliff, T. L. (1995). EFFECT OF INFLAMMATION AND BENIGN PROSTATIC HYPERPLASIA ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS. Journal of Urology, 154(2), 407-413. doi:10.1016/s0022-5347(01)67064-2
275 11.96
63 Narayan, P., Tewari, A., & Grp, U. S. S. (1998). A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. Journal of Urology, 160(5), 1701-1706. doi:10.1016/s0022-5347(01)62386-3
141 7.05
64 Nickel, J. C., Downey, J., Young, I., & Boag, S. (1999). Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. Bju International, 84(9), 976-981.
206 10.84
65 Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., . . . Williams, J. A. (1996). Efficacy and safety off finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT Study). Canadian Medical Association Journal, 155(9), 1251-1259.
161 7.32
66 Oelke, M., Giuliano, F., Mirone, V., Xu, L., Cox, D., & Viktrup, L. (2012).
Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International,
Randomised, Parallel, Placebo-Controlled Clinical Trial. European Urology, 61(5), 917-925. doi:10.1016/j.eururo.2012.01.013
HYPERPLASIA - MEDICAL AND MINIMALLY INVASIVE TREATMENT OPTIONS. New England Journal of Medicine, 332(2), 99-109.
doi:10.1056/nejm199501123320207
68 Oto, A., Kayhan, A., Jiang, Y. L., Tretiakova, M., Yang, C., Antic, T., . . . Stadler, W. M. (2010). Prostate Cancer: Differentiation of Central Gland Cancer from Benign Prostatic Hyperplasia by Using Diffusion-weighted and Dynamic Contrast-enhanced MR Imaging. Radiology, 257(3), 715-723. doi:10.1148/radiol.10100021
153 19.13
69 Ozden, C., Ozdal, O. L., Uryancioglu, G., Koyuncu, H., Gokkaya, S., & Memis, A. (2007). The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urology, 51(1), 199-206.
doi:10.1016/j.eururo.2006.05.040
145 13.18
70 Parsons, J. K., Carter, H. B., Partin, A. W., Windham, B. G., Metter, E. J., Ferrucci, L., . . . Platz, E. A. (2006). Metabolic factors associated with benign prostatic hyperplasia. Journal of Clinical Endocrinology & Metabolism, 91(7), 2562-2568. doi:10.1210/jc.2005-2799
190 15.83
71 Partin, A. W., Getzenberg, R. H., Carmichael, M. J., Vindivich, D., Yoo, J., Epstein, J. I., & Coffey, D. S. (1993). NUCLEAR MATRIX PROTEIN-PATTERNS IN HUMAN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE-CANCER. Cancer Research, 53(4), 744-746.
142 5.68
72 Partin, A. W., Oesterling, J. E., Epstein, J. I., Horton, R., & Walsh, P. C. (1991). INFLUENCE OF AGE AND ENDOCRINE FACTORS ON THE VOLUME OF BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 145(2), 405-409. doi:10.1016/s0022-5347(17)38353-2
140 5.19
73 Penna, G., Mondaini, N., Amuchastegui, S., Innocenti, S. D., Carini, M., Giubilei, G., . . . Adorini, L. (2007). Seminal plasma cytokines and chemokines in prostate
inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European Urology, 51(2), 524-533. doi:10.1016/j.eururo.2006.07.016
141 12.82
74 Peters, C. A., & Walsh, P. C. (1987). THE EFFECT OF NAFARELIN ACETATE, A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST, ON BENIGN PROSTATIC HYPERPLASIA. New England Journal of Medicine, 317(10), 599-604. doi:10.1056/nejm198709033171004
279 9.00
75 Peters, T. J., Donovan, J. L., Kay, H. E., Abrams, P., delaRosette, J., Porru, D., . . . Walter. (1997). The international continence society ''benign prostatic hyperplasia'' study: The bothersomeness of urinary symptoms. Journal of Urology, 157(3), 885-889. doi:10.1016/s0022-5347(01)65075-4
239 11.38
76 Reich, O., Gratzke, C., & Stief, C. G. (2006). Techniques and long-term results of surgical procedures for BPH. European Urology, 49(6), 970-978.
doi:10.1016/j.eururo.2005.12.072
164 13.67
77 Roehrborn, C. G., Boyle, P., Gould, A. L., & Waldstreicher, J. (1999). Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology, 53(3), 581-589. doi:10.1016/s0090-4295(98)00655-4
206 10.84
78 Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., Investigators, A. S., . . . Investigators, A. S. (2002). Efficacy and safety of a dual inhibitor of
reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60(3), 434-441. doi:10.1016/s0090-4295(02)01905-2
79 Roehrborn, C. G., McConnell, J. D., Lieber, M., Kaplan, S., Geller, J., Malek, G. H., . . . Grp, P. S. (1999). Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology, 53(3), 473-480. doi:10.1016/s0090-4295(98)00654-2
209 11.00
80 Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Lloyd, L. K., Milam, D. E., & Padley, R. J. (1996). The Hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology, 47(2), 159-168. doi:10.1016/s0090-4295(99)80409-9
167 7.59
81 Roehrborn, C. G., & Schwinn, D. A. (2004). alpha(1)-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. Journal of Urology, 171(3), 1029-1035. doi:10.1097/01.ju.0000097026.43866.cc
186 13.29
82 Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A., & Viktrup, L. (2008). Tadalafil administered once daily for lower urinary tract symptoms secondary to benign
prostatic hyperplasia: A dose finding study. Journal of Urology, 180(4), 1228-1234. doi:10.1016/j.juro.2008.06.079
176 17.60
83 Roehrborn, C. G., Siami, P., Barkin, J., Damiao, R., Major-Walker, K., Morrill, B., . . . Comb, A. T. S. G. (2008). The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Journal of Urology, 179(2), 616-621. doi:10.1016/j.juro.2007.09.084
176 17.60
84 Roehrborn, C. G., Siami, P., Barkin, J., Damiao, R., Major-Walker, K., Nandy, I., . . . Comb, A. T. S. G. (2010). The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic
Hyperplasia: 4-Year Results from the CombAT Study. European Urology, 57(1), 123-131. doi:10.1016/j.eururo.2009.09.035
323 40.38
85 Roos, N. P., Wennberg, J. E., Malenka, D. J., Fisher, E. S., McPherson, K., Andersen, T. F., . . . Ramsey, E. (1989). MORTALITY AND REOPERATION AFTER OPEN AND TRANS-URETHRAL RESECTION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA. New England Journal of Medicine, 320(17), 1120-1124. doi:10.1056/nejm198904273201705
494 17.03
86 Shapiro, E., Hartanto, V., & Lepor, H. (1992). THE RESPONSE TO ALPHA-BLOCKADE IN BENIGN PROSTATIC HYPERPLASIA IS RELATED TO THE PERCENT AREA DENSITY OF PROSTATE SMOOTH-MUSCLE. Prostate, 21(4), 297-307. doi:10.1002/pros.2990210406
140 5.38
87 Stamey, T. A., Warrington, J. A., Caldwell, M. C., Chen, Z. X., Fan, Z. B.,
Mahadevappa, M., . . . Zhang, Z. M. (2001). Molecular genetic profiling of gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. Journal of Urology, 166(6), 2171-2177. doi:10.1016/s0022-5347(05)65528-0
144 8.47
88 Stief, C. G., Porst, H., Neuser, D., Beneke, M., & Ulbrich, E. (2008). A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology, 53(6), 1236-1244. doi:10.1016/j.eururo.2008.01.075
INHIBITOR, FINASTERIDE, ON BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 147(5), 1298-1302. doi:10.1016/s0022-5347(17)37547-x
90 Stoner, E., Andriole, G. L., Boake, R., Bracken, B. R., Brannan, W., Fuselier, H., . . . Charig, C. (1994). 3-YEAR SAFETY AND EFFICACY DATA ON THE USE OF FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC
HYPERPLASIA. Urology, 43(3), 284-294. doi:10.1016/0090-4295(94)90068-x
167 6.96
91 Tan, A. H. H., Gilling, P. J., Kennett, K. M., Frampton, C., Westenberg, A. M., & Fraundorfer, M. R. (2003). A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). Journal of Urology, 170(4), 1270-1274.
doi:10.1097/01.ju.0000086948.55973.00
187 12.47
92 Te, A. E., Malloy, T. R., Stein, B. S., Ulchaker, J. C., Nseyo, U. O., Hai, M. A., & Malek, R. S. (2004). Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. Journal of Urology, 172(4), 1404-1408.
doi:10.1097/01.ju.0000139541.68542.f6
167 11.93
93 Theyer, G., Kramer, G., Assmann, I., Sherwood, E., Preinfalk, W., Marberger, M., . . . Steiner, G. E. (1992). PHENOTYPIC CHARACTERIZATION OF
INFILTRATING LEUKOCYTES IN BENIGN PROSTATIC HYPERPLASIA. Laboratory Investigation, 66(1), 96-107.
152 5.85
94 Thorpe, A., & Neal, D. (2003). Benign prostatic hyperplasia. Lancet, 361(9366), 1359-1367. doi:10.1016/s0140-6736(03)13073-5
147 9.80
95 Untergasser, G., Madersbacher, S., & Berger, P. (2005). Benign prostatic hyperplasia: age-related tissue-remodeling. Experimental Gerontology, 40(3), 121-128.
doi:10.1016/j.exeger.2004.12.008
144 11.08
96 Verhamme, K. M. C., Dieleman, J. P., Bleumink, G. S., van der Lei, J., &
Sturkenboom, M. (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - The Triumph project. European Urology, 42(4), 323-328. doi:10.1016/s0302-2838(02)00354-8
177 11.06
97 Wasson, J. H., Reda, D. J., Bruskewitz, R. C., Elinson, J., Keller, A. M., &
Henderson, W. G. (1995). A COMPARISON OF TRANSURETHRAL SURGERY WITH WATCHFUL WAITING FOR MODERATE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. New England Journal of Medicine, 332(2), 75-79. doi:10.1056/nejm199501123320202
403 17.52
98 Wei, J. T., Calhoun, E., & Jacobsen, S. J. (2005). Urologic diseases in America project: Benign prostatic hyperplasia. Journal of Urology, 173(4), 1256-1261. doi:10.1097/01.ju.0000155709.37840.fe
276 21.23
99 Wilson, J. D. (1980). THE PATHOGENESIS OF BENIGN PROSTATIC
HYPERPLASIA. American Journal of Medicine, 68(5), 745-756. doi:10.1016/0002-9343(80)90267-3
322 8.47
100 Wilt, T. J., Ishani, A., Stark, G., MacDonald, R., Lau, J., & Mulrow, C. (1998). Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review. Jama-Journal of the American Medical Association, 280(18), 1604-1609.
doi:10.1001/jama.280.18.1604
